NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation

NNASDAQ:NMTC
0.75
USD
+0.00
(-0.01%)
-0.88EPS
26.46MMarket Cap
Dec 16Next Earn
NeuroOne Medical Technologies Corporation
NASDAQ:NMTC
(Nasdaq Stock Market)

Recent

price

0.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.1
0.06
0.65
0.77
1.36
1.12
Revenue per Share
-0.03
-0.11
-0.05
-0.11
-0.13
-0.22
-0.17
-13.77
- -
-10.29
-15.11
-5.58
-3.75
-3.93
-2.76
-0.54
-0.88
Basic EPS, GAAP
-0.02
-0.11
-0.05
-0.09
-0.09
-0.11
-0.07
-5.99
- -
-8.38
-3.93
-4.86
-2.92
-4.39
-2.5
-0.44
-0.85
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-0.01
-0.06
-0.11
-0.13
-0.29
-0.94
-11.53
-8.19
-1.65
1.68
3.27
3.55
1.57
0.16
0.85
0.43
Book Value per Share
-0.02
-0.01
-0.06
-0.11
-0.13
-0.29
-1.59
-12.02
-8.57
-1.89
1.55
3.21
3.51
1.54
0.15
0.84
0.43
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
3
3
4
7
8
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
3
9
9
Sales/Revenue/Turnover
-517.91
-508.11
-1,491.1
-2,009.05
-4,646.05
-4,166.44
- -
- -
- -
- -
- -
-5,735.86
-5,860.15
-612.32
-344.26
-46.46
-83.43
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
-5
- -
-7
-14
-10
-10
-12
-12
-4
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-517.91
-511.37
-1,515.74
-2,446.28
-4,688.75
-8,472.1
- -
- -
- -
- -
- -
-5,584.28
-5,841.95
-607.42
-356.74
-39.63
-78.63
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-4
-4
-1
2
6
9
6
2
8
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
-5
-4
-1
2
7
10
6
1
7
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-230.81
-123.77
-149.61
-348.39
-91.34
-124.66
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
9
9
Market Capitalization
38
40
26

Working Capital

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
8
7
6
Cash, Cash Equivalents & STI
4
3
2
Accounts Receivable, Net
3
2
1
Inventories
2
2
2
Total Current Liabilities
1
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
256.94%
180.47%
760.39%
Free Cash Flow
- -
22.93%
-73.78%
Net Income, GAAP
- -
-14.96%
-70.73%
Sales/Revenue/Turnover
- -
- -
163.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
- -
3
2025
3
1
2
3
9
2026
3
2
2
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.84
-0.66
-0.61
-0.67
-2.76
2025
0.35
-0.44
-0.19
-0.19
-0.54
2026
-0.17
-0.28
-0.23
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), founded in 2009 and headquartered in Eden Prairie, Minnesota, develops and commercializes minimally invasive, high-definition thin-film electrode technology for diagnostic and therapeutic neurological applications, primarily targeting epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain from failed back surgeries, and other brain-related disorders in the United States. The company's core products include Evo cortical electrodes for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrodes for temporary subsurface brain signal recording, monitoring, and stimulation; and the OneRF radiofrequency ablation system, the world's first FDA-cleared platform for both diagnostic and therapeutic procedures using sEEG electrodes to create lesions in nervous tissue for functional neurosurgery, including trigeminal neuralgia treatment following a recent FDA 510(k) submission. It also pursues applications in spinal cord stimulation, brain stimulation, drug delivery, depression, mood disorders, incontinence, and artificial intelligence-integrated neuromodulation solutions. Recent developments encompass an expanded exclusive distribution agreement with Zimmer Biomet, granting rights to distribute the OneRF system for brain applications with a $3 million upfront payment and potential milestone payments to drive U.S. and international commercialization; a $2.65 million equity financing and $3 million credit facility in 2024 to support operations through mid-2025; filing of a 510(k) submission ahead of schedule for OneRF trigeminal nerve ablation; and appointment of neurosurgeon Dr. Parag Patil as Chief Medical Advisor to advance clinical strategies.

Company News

  • NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System

  • NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain

  • NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

  • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Short Interest Climbs 135.8%

  • NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

  • NeuroOne (NASDAQ: NMTC) secures a $4.5M order as revenue climbs again

  • NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

  • Innovative Eyewear (NASDAQ:LUCY) and NeuroOne Medical Technologies (NASDAQ:NMTC) Head-To-Head Review

  • $10 Million in New Markets Tax Credit Financing for a New cold Storage and Refrigerated Logistics Facility in Albertville, AL

  • Analysts Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Price Target at $7.33

  • NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

  • $6 Million in New Markets Tax Credit Financing for the Acquisition, Renovation, and Equipping of a Tractor Assembly Facility in Monroeville, AL

  • NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

  • NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

  • Analyzing First Choice Healthcare Solutions (OTCMKTS:FCHS) & NeuroOne Medical Technologies (NASDAQ:NMTC)

  • NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

  • Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98

  • NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

  • NeuroOne Medical Technologies (NASDAQ:NMTC) versus Aclarion (NASDAQ:ACON) Head to Head Contrast

  • Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)